SCHEMBL30596901

SCHEMBL30596901

CC(C)(C)OC(=O)Nc1cc2cnccc2cc1F

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 4/20 0.52
PRMT3 O60678 2/20 0.49
NAMPT P43490 1/20 0.42
SYK P43405 1/20 0.41
BRAF P15056 1/20 0.41
ACVR1B P36896 1/20 0.41
TGFBR1 P36897 1/20 0.41
ACVRL1 P37023 1/20 0.41
IMPDH2 P12268 2/20 0.38
RAB9A P51151 1/20 0.38
AAK1 Q2M2I8 1/20 0.38
CLK1 P49759 1/20 0.38
CLK2 P49760 1/20 0.38
CLK3 P49761 1/20 0.38
CDK5 Q00535 1/20 0.38
DYRK1A Q13627 1/20 0.38
CDK5R1 Q15078 1/20 0.38
CLK4 Q9HAZ1 1/20 0.38
DYRK1B Q9Y463 1/20 0.38
TRPV1 Q8NER1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26107591 1.00 CYP17A1 (0.52) CYP17A1PRMT3NAMPTSYKBRAF
SCHEMBL25859564 0.84 CLK1 (0.41) CYP17A1NAMPTRAB9ACLK1CLK2
SCHEMBL16307603 0.81 CYP17A1 (0.55) CYP17A1NAMPTSYKACVR1BTGFBR1
SCHEMBL15039524 0.81 CYP17A1 (0.55) CYP17A1NAMPTSYKACVR1BTGFBR1
SCHEMBL30627587 0.77 NQO2 (0.47) PRMT3NAMPTACVR1BTGFBR1ACVRL1
SCHEMBL30627557 0.77 NQO2 (0.47) PRMT3NAMPTACVR1BTGFBR1ACVRL1
SCHEMBL30381667 0.76 DYRK1A (0.54) CYP17A1NAMPTSYKRAB9ACLK2
SCHEMBL18522430 0.76 NAMPT (0.50) CYP17A1NAMPTRAB9ABRS3
SCHEMBL14725520 0.76 CYP17A1 (0.48) CYP17A1SYKBRAFAAK1
SCHEMBL5746021 0.75 NAMPT (0.47) CYP17A1NAMPTRAB9AAAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4504730-A1 DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 Dana-Farber Cancer Institute, Inc. (US) 2025-02-12 EP disclosed
WO-2023196409-A1 DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-10-12 WO disclosed